



## News Release

22 July 2015

### SGX welcomes iX Biopharma Ltd to Catalist

Singapore Exchange (SGX) today welcomed iX Biopharma Ltd (iX Biopharma) to Catalist under the stock code "42C".

iX Biopharma is a Singapore incorporated pharmaceutical company focused on the development and commercialisation of products for the treatment of acute pain and erectile dysfunction. It also provides chemical analysis services for pharmaceutical products. iX Biopharma manages and undertakes its research and development in Singapore and Australia.

Professor Paul Edward Rolan, Director of Drug Development, iX Biopharma said, "This listing is significant as it brings us a step closer towards our goal of commercialising our products currently under development. We are also heartened by the confidence that our shareholders have in the Company. We look forward to completing our clinical trials in a timely manner, and promise to work hard to create good value for them."

Mohamed Nasser Ismail, Head of SME Development & Listing, SGX, said, "We are pleased to welcome iX Biopharma to SGX. With an increasing focus on healthcare and improved therapies in the region, iX Biopharma is well-placed to benefit from the resultant growth in its industry. We look forward to supporting the company on its growth journey."

The listing of iX Biopharma brings the total number of healthcare companies on SGX to 31 with a combined market capitalisation of over S\$38 billion. Following iX Biopharma's IPO, the Catalist board will have 160 companies with a total market capitalisation of about S\$10 billion.

iX Biopharma opened at \$0.495 today, 8% up from the offer price.

-End-

#### About iX Biopharma Ltd

iX Biopharma Ltd is a late-stage specialty pharmaceutical company specialising in the development and commercialisation of innovative therapies for pain management and male erectile dysfunction. The Company leverages its patented sublingual drug delivery technology, WaferiX™, to develop proprietary products that incorporate FDA-approved pharmacologically active compounds. It has three products in the late stages of clinical development: Wafermine™, its lead product, Wafernyl™ for the treatment of pain, and PheoniX™ for the treatment of male erectile dysfunction.

### **About Singapore Exchange (SGX)**

Singapore Exchange (SGX) is the Asian connecting investors in search of Asian growth to corporate issuers in search of global capital. SGX represents the premier access point for managing Asian capital and investment exposure, and is Asia's most international exchange with about 40% of companies listed on SGX originating outside of Singapore. SGX offers its clients the world's biggest offshore market for Asian equity index futures, centred on Asia's three largest economies – China, India and Japan.

In addition to offering a fully integrated value chain from trading and clearing, to settlement and depository services, SGX is also Asia's pioneering central clearing house. Headquartered in Asia's most globalised city, and centred within the AAA strength and stability of Singapore's island nation, SGX is a leading Asian counterparty for the clearing of financial and commodity products.

For more information, please visit [www.sgx.com](http://www.sgx.com)

### **Media Contacts**

Ying Wang  
Marketing & Communications  
+65 6713 7253  
[ying.wang@sgx.com](mailto:ying.wang@sgx.com)

**Singapore Exchange**  
2 Shenton Way  
#02-02 SGX Centre 1  
Singapore 068804  
main: +65 6236 8888  
**[sgx.com](http://sgx.com)**